Stockscreener 앱 받기
4.4886
4.95%
-0.1614
전일 마감가:
$4.65
열려 있는:
$4.5
하루 거래량:
246.31K
Relative Volume:
0.06
시가총액:
$580.29M
수익:
-
순이익/손실:
$-110.78M
주가수익비율:
-5.1593
EPS:
-0.87
순현금흐름:
$-75.59M
1주 성능:
+18.84%
1개월 성능:
+0.45%
6개월 성능:
-11.57%
1년 성능:
+56.60%
1일 변동 폭
$4.40
$4.50
1주일 범위
$3.37
$6.77
52주 변동 폭
$2.48
$9.97
Humacyte Inc Stock (HUMA) Company Profile
명칭
Humacyte Inc
전화
919-313-9633
주소
2525 EAST NORTH CAROLINA HIGHWAY 54, DURHAM
HUMA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HUMA
Humacyte Inc
|
4.49 | 580.29M | 0 | -110.78M | -75.59M | -1.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
408.36 | 105.12B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
714.47 | 78.51B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
629.99 | 37.67B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
240.98 | 31.37B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
114.12 | 27.36B | 3.30B | -501.07M | 1.03B | -2.1146 |
Humacyte Inc Stock (HUMA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-12-20 | 재확인 | H.C. Wainwright | Buy |
| 2023-12-11 | 개시 | H.C. Wainwright | Buy |
| 2023-08-14 | 업그레이드 | Piper Sandler | Underweight → Neutral |
| 2023-06-22 | 개시 | Cantor Fitzgerald | Overweight |
| 2022-05-16 | 다운그레이드 | Piper Sandler | Overweight → Underweight |
| 2021-10-29 | 개시 | Cowen | Outperform |
| 2021-09-24 | 개시 | Oppenheimer | Outperform |
| 2021-09-22 | 개시 | BTIG Research | Buy |
| 2021-09-16 | 개시 | Piper Sandler | Overweight |
모두보기
Humacyte Inc 주식(HUMA)의 최신 뉴스
Humacyte (NASDAQ:HUMA) Sees Unusually-High Trading Volume on Analyst Upgrade - Defense World
ROSEN, A LONGSTANDING FIRM, Encourages Humacyte, Inc. - GlobeNewswire
HUMA LAWSUIT ALERT: Levi & Korsinsky Notifies Humacyte, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AccessWire
HUMACYTE ALERT: Bragar Eagel & Squire, P.C. Announces that - GlobeNewswire
Humacyte's Symvess Debut: A Milestone With Lingering Concerns (Rating Downgrade) - Seeking Alpha
Lost Money on Humacyte, Inc.(HUMA)? Join Class Action Suit Seeking RecoveryContact Levi & Korsinsky - AccessWire
HUMA SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte (NASDAQ:HUMA) Sees Strong Trading Volume Following Analyst Upgrade - MarketBeat
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Benzinga
Humacyte (NASDAQ:HUMA) Price Target Raised to $17.00 at Benchmark - MarketBeat
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein - GlobeNewswire
HUMACYTE, INC. (NASDAQ: HUMA) DEADLINE ALERT: Bernstein Liebhard LLP Reminds Humacyte, Inc. - The Bakersfield Californian
State Street Corp Buys 1,895,529 Shares of Humacyte, Inc. (NASDAQ:HUMA) - Defense World
Humacyte, Inc. (NASDAQ:HUMA) Shares Purchased by State Street Corp - MarketBeat
Humacyte’s (HUMA) Buy Rating Reiterated at D. Boral Capital - Defense World
Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - AccessWire
2024-12-22 | Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More | NDAQ:HUMA | Press Release - Stockhouse Publishing
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Stockholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
INVESTOR DEADLINE APPROACHING: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Humacyte - AccessWire
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Invests $596,000 in Humacyte, Inc. (NASDAQ:HUMA) - MarketBeat
HUMA Investors Have Opportunity to Lead Humacyte, Inc. Securities Fraud Lawsuit - The Eastern Progress Online
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Humacyte, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - GlobeNewswire Inc.
Shareholders of Humacyte, Inc. Should Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
Humacyte, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before January 17, 2025 to Discuss Your RightsHUMA - AccessWire
Humacyte Receives FDA Approval for SYMVESS Launch - TipRanks
Why Is Bioengineered Human Tissue-Focused Humacyte Stock Surging On Friday? - AOL
FDA approves Humacyte’s lab-grown blood vessels in milestone for regenerative medicine - Endpoints News
Glancy Prongay & Murray LLP Reminds Investors of Looming - GlobeNewswire
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against - EIN News
Humacyte stock surge in question: can it sustain today's gains? - Invezz
Humacyte stock may fail to sustain today’s gains: find out more - TradingView
FDA approval propels North Carolina company's breakthrough treatment for trauma patients - Triangle Business Journal
Humacyte’s tissue-engineered graft for vascular trauma approved by FDA - BioWorld Online
Shareholders That Lost Money on Humacyte, Inc. (HUMA) Urged to Join Class ActionContact Levi & Korsinsky to Learn More - AccessWire
US FDA approves Humacyte’s Symvess for vascular trauma - Vascular News
HUMA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Humacyte, Inc. Shareholders Have Opportunity to Lead Class Action Lawsuit! - AccessWire
Humacyte Stock Hits Over 1-Month Highs On FDA Nod For Bioengineered Tissue In Treating Vascular Trauma, Retail - Asianet Newsable
Humacyte (NASDAQ:HUMA) Given Buy Rating at D. Boral Capital - MarketBeat
Humacyte (NASDAQ:HUMA) Shares Gap UpTime to Buy? - MarketBeat
Spotlight on Humacyte: Analyzing the Surge in Options Activity - Benzinga
Huma Stock Surges Following FDA Approval of Groundbreaking Bioengineered Vascular Conduit - The Africa Logistics
BTIG reiterates Buy on Humacyte stock as FDA approval of SYMVESS boosts commercialization prospects - Investing.com South Africa
Humacyte's (HUMA) "Buy" Rating Reiterated at HC Wainwright - MarketBeat
Humacyte's bioengineered human tissue gains FDA approval - FirstWord Pharma
Humacyte shares target raised, buy rating held on FDA approval - Investing.com
Humacyte surges on FDA approval for Symvess vascular repair product - MSN
Humacyte stock surges over 50% on FDA approval - Investing.com
Humacyte Shares Surge 38% on FDA Approval of Symvess - Marketscreener.com
Shareholders that lost money on Humacyte, Inc.(HUMA) Urged to Jo - GuruFocus.com
FDA Approves Humacyte's Groundbreaking Bioengineered Blood Vessel Treatment SYMVESS in Historic First - StockTitan
Humacyte's SYMVESS gets FDA nod for vascular trauma - Investing.com
Humacyte Inc (HUMA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.10%
0.76%
자본화:
|
볼륨(24시간):